Clinical Trial Update: Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS) [Phase 2]

View source ↗

Summary

Phase 2 VENUS study evaluating the safety and efficacy of LX102 gene therapy for neovascular age-related macular degeneration; the trial is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• LX102

Snippet

Sponsor: Innostellar Biotherapeutics Co.,Ltd | Conditions: Neovascular Age-Related Macular Degeneration | Phase 2 | Status: ACTIVE_NOT_RECRUITING